Society for Immunotherapy of Cancer Publishes Clinical Practice Guideline on Immunotherapy for the Treatment of Multiple Myeloma

Share Article

The Society for Immunotherapy of Cancer (SITC), the world’s leading member-driven organization dedicated solely to cancer immunotherapy, has published a clinical practice guideline specific to the use of immunotherapy for multiple myeloma, a type of blood cancer.

SITC Cancer Immunotherapy Guidelines

SITC Cancer Immunotherapy Guidelines

“Through our immunotherapy clinical practice guidelines, SITC provides an important resource for clinicians in developing treatment plans aimed at the best possible outcomes for their patients," said SITC President Mario Sznol, MD.

The Society for Immunotherapy of Cancer (SITC), the world’s leading member-driven organization dedicated solely to cancer immunotherapy, has published a clinical practice guideline specific to the use of immunotherapy for multiple myeloma, a type of blood cancer.

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma,” was developed by an expert panel of leaders in the fields of hematology, oncology, hematopathology, oncology nursing and cancer patient advocacy from across the United States. This immunotherapy-specific guideline provides oncologists and other advanced practice providers a clinical roadmap to provide optimal care for patients who have multiple myeloma.

Our SITC expert panel developed this manuscript to help provide medical oncologists with expert guidance for incorporating the various approved and emerging immunotherapy agents and regimens into their practice,” said Madhav Dhodapka, MD, co-chair of the SITC Multiple Myeloma Immunotherapy Gudeline Expert Panel.

Published in the Journal for ImmunoTherapy of Cancer (JITC), the society’s open access, peer-reviewed online journal, this guideline is an update to the society’s previous 2016 manuscript on hematologic malignancies, which included lymphoma and acute leukemia in addition to multiple myeloma.

“Combination regimens including immunotherapies such as the antibody therapies daratumumab and elotuzumab have become a mainstay in recent years for multiple myeloma and some patients have benefited tremendously,” said Nina Shah, MD, co-chair of the SITC Multiple Myeloma Immunotherapy Guideline Expert Panel. “What’s more, novel agents such as CAR T cell therapies and bispecific T cell engagers are also showing encouraging results in late-stage trials.”

The SITC Cancer Immunotherapy Guidelines are a collection of clinical practice guidelines (CPGs) developed by leading experts to help hematologists and oncologists determine when and how to best use immunotherapy to treat their patients. The guidelines cover immunotherapy treatment recommendations, toxicity management and considerations for patient quality of life. SITC has published CPGs for bladder carcinoma, cutaneous melanoma, head and neck squamous cell carcinoma, hematologic malignancies, non-small cell lung cancer, prostate cancer and renal cell carcinoma. Additional guidelines are in development covering acute leukemia and lymphoma as well as breast cancer, hepatocellular carcinoma, non-melanoma skin cancer and immune-related adverse events.

“SITC as an organization is dedicated to advancing both the science and application of cancer immunotherapy,” said SITC President Mario Sznol, MD. “Through our immunotherapy clinical practice guidelines, SITC provides an important resource for clinicians in developing treatment plans aimed at the best possible outcomes for their patients.”

In addition to the published manuscript, SITC is also offering a number of different opportunities to help clinicians understand and implement the guidelines into their practice. On such resource are the live webinars and on-demand modules hosted on the SITC website. On Sept. 3, 2020, at 7 p.m. EDT, SITC will host a live, free webinar during which attendees will be able to learn more about the treatment recommendations within the Multiple Myeloma guidelines and ask questions of expert faculty. Click here to view past SITC Cancer Immunotherapy Guidelines webinars on-demand.

About SITC
Established in 1984, the Society for Immunotherapy of Cancer (SITC) is a nonprofit organization of medical professionals dedicated to improving cancer patient outcomes by advancing the development, science and application of cancer immunotherapy and tumor immunology. SITC is comprised of influential basic and translational scientists, practitioners, health care professionals, government leaders and industry professionals around the globe. Through educational initiatives that foster scientific exchange and collaboration among leaders in the field, SITC aims to one day make the word “cure” a reality for cancer patients everywhere. Learn more about SITC, our educational offerings and other resources at sitcancer.org and follow us on Twitter, LinkedIn, Facebook and YouTube.

About JITC
Journal for ImmunoTherapy of Cancer (JITC) is the official open access, peer-reviewed online journal of the Society for Immunotherapy of Cancer featuring an impact factor of 9.913. The journal publishes high-quality articles on all aspects of tumor immunology and cancer immunotherapy, on subjects across the basic science-translational-clinical spectrum. JITC publishes original research articles, literature reviews, position papers and practice guidelines, and case reports; invited commentaries may also be commissioned by the journal editors. These articles, freely accessible at jitc.bmj.com, make JITC the leading forum for tumor immunology and cancer immunotherapy research. Follow JITC on Twitter @jitcancer.

# # #

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Julia Schultz
SITC
414-271-2456
Email >
@sitcancer
Follow >
Society for Immunotherapy of Cancer
Like >
Visit website